The article Cybin Doses Last Patient in Part B of Phase 1 DMT Trial was originally published on Microdose. Cybin moves its DMT program forward as...
The article Which Psychedelic Medicine Companies Have the Best Financials? was originally published on Microdose. As I have written many times before,...
The first three months of 2023 have been a whirlwind for the psychedelic industry– to say the least. Though it has been a particularly difficult quarter,...
Truffle Report has compiled a roundup of major psychedelic business news stories from the week of February 7-11, making it easier for you to access these...
Cybin Inc. (NEO:CYBN / NYSE American:CYBN) a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
SkyQuest's Psychedelic Drugs Market report provides actionable insights for individuals interested in valuable data, trends, and opportunities in a rapidly...
Dublin, April 27, 2023 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering....
Count Deepak Chopra among the medical experts who see enormous promise in psychedelic substances like psilocybin or “magic mushrooms.” “I think psychedelics...
While not illegal, some people are vehemently opposed to the practice. The post The Positives and Pitfalls of Paid Stock Promotion appeared first on Green...
The"Multi-bagger" Portfolio was UP 5.7% in March but is still DOWN 12.7% YTD (the S&P 500 which was UP 5.2% in March and is UP 7.0% YTD) and...